AptarGroup, Inc. (NYSE:ATR) Stock Now Rated “Moderate Buy” by Wall Street Analysts

by · The Markets Daily

Shares of AptarGroup, Inc. (NYSE:ATR – Get Free Report) have earned an average recommendation of “Moderate Buy” from the eight analysts that are currently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $172.80.

ATR has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AptarGroup in a research note on Monday, September 21st. Wells Fargo & Company increased their price target on shares of AptarGroup from $145.00 to $155.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Raymond James Financial reissued an “outperform” rating and issued a $160.00 price target on shares of AptarGroup in a report on Wednesday, July 15th. Finally, Bank of America upgraded shares of AptarGroup from a “neutral” rating to a “buy” rating and set a $173.00 price objective for the company in a research report on Tuesday, July 14th.

Get Our Latest Stock Analysis on AptarGroup

AptarGroup Stock Performance

Shares of NYSE:ATR opened at $123.77 on Wednesday. AptarGroup has a twelve month low of $103.23 and a twelve month high of $146.91. The firm has a market cap of $7.87 billion, a PE ratio of 22.38, a price-to-earnings-growth ratio of 3.16 and a beta of 0.38. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.10 and a current ratio of 1.61. The business has a fifty day moving average of $130.42 and a 200-day moving average of $125.70.

AptarGroup (NYSE:ATR – Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The industrial products company reported $1.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.35 by $0.07. AptarGroup had a return on equity of 13.31% and a net margin of 9.22%.The business had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same period in the previous year, the business posted $1.66 earnings per share. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. AptarGroup has set its Q3 2026 guidance at 1.450-1.530 EPS. On average, equities research analysts predict that AptarGroup will post 5.48 EPS for the current fiscal year.

AptarGroup Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, August 20th. Stockholders of record on Thursday, July 30th were paid a $0.48 dividend. This represents a $1.92 annualized dividend and a dividend yield of 1.6%. The ex-dividend date of this dividend was Thursday, July 30th. AptarGroup’s dividend payout ratio (DPR) is 34.72%.

Insider Transactions at AptarGroup

In other news, insider Shiela Vinczeller sold 765 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $130.37, for a total transaction of $99,733.05. Following the completion of the sale, the insider owned 26,313 shares in the company, valued at $3,430,425.81. The trade was a 2.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Gael Touya sold 3,740 shares of the company’s stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $133.76, for a total value of $500,262.40. Following the transaction, the chief executive officer directly owned 29,102 shares in the company, valued at $3,892,683.52. This trade represents a 11.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 23,197 shares of company stock worth $3,134,828. Insiders own 0.73% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Parkside Financial Bank & Trust grew its stake in shares of AptarGroup by 41.9% during the second quarter. Parkside Financial Bank & Trust now owns 298 shares of the industrial products company’s stock worth $37,000 after purchasing an additional 88 shares during the period. State of Wyoming lifted its stake in AptarGroup by 4.5% in the first quarter. State of Wyoming now owns 2,252 shares of the industrial products company’s stock valued at $284,000 after buying an additional 98 shares during the period. IFP Advisors Inc lifted its stake in AptarGroup by 47.0% in the fourth quarter. IFP Advisors Inc now owns 369 shares of the industrial products company’s stock valued at $45,000 after buying an additional 118 shares during the period. Hanson & Doremus Investment Management boosted its holdings in AptarGroup by 0.7% during the first quarter. Hanson & Doremus Investment Management now owns 17,632 shares of the industrial products company’s stock worth $2,222,000 after buying an additional 130 shares during the last quarter. Finally, Geneos Wealth Management Inc. boosted its holdings in AptarGroup by 214.1% during the first quarter. Geneos Wealth Management Inc. now owns 201 shares of the industrial products company’s stock worth $25,000 after buying an additional 137 shares during the last quarter. 88.52% of the stock is currently owned by institutional investors and hedge funds.

About AptarGroup

(Get Free Report)

AptarGroup, Inc is a global supplier of dispensing, packaging and drug-delivery solutions. The company develops and manufactures pumps, valves, aerosol systems, closures, dispensing devices and other components used to package and deliver products in the pharmaceutical, beauty, personal care, food and beverage markets.

Its pharmaceutical offerings include nasal, respiratory, ophthalmic and dermal drug-delivery systems, as well as components and technologies designed to support the administration of prescription and consumer healthcare products.

See Also